Quantum BioPharma Ltd. (NASDAQ: QNTM) disclosed results of its Nov. 10, 2026 annual general and special meeting and confirmed the closing of a non-brokered private placement of 26 Class A multiple voting shares on Nov. 9, a transaction that meaningfully concentrates voting control in the hands of company insiders despite raising only nominal capital.
Shareholders elected all five director nominees, reappointed MNP LLP as auditor and approved several resolutions, according to the announcement from Quantum BioPharma (NASDAQ: QNTM). The approved measures include authorization to issue additional Class A multiple voting shares to maintain up to 70% aggregate voting power, a 2026 omnibus equity incentive plan, a potential share consolidation at a ratio of up to 10-for-1 and a potential corporate name change. The board retains discretion over whether to implement any of these measures.
The private placement itself was small in dollar terms: 26 Class A multiple voting shares were issued at C$3.11 per share, generating gross proceeds of C$80.86. Xorax Family Trust, associated with CEO Zeeshan Saeed, and Fortius Research and Trading Corp., controlled by director Anthony Durkacz, each acquired 13 shares. Following the placement, the aggregate voting power of Class A multiple voting shares rose from approximately 57.01% to 68.22%.
The transaction was completed under shareholder authorization granted in 2025, with proceeds designated for general working capital purposes. The full press release is available at https://ibn.fm/UagXR.
The governance implications matter for public investors. A tiny outlay of capital moved nearly 11 percentage points of aggregate voting power toward insiders, and the newly approved authorization allows the company to issue further multiple voting shares to sustain up to 70% aggregate voting power. For a Nasdaq-listed biopharmaceutical company, that structure can limit the influence of ordinary shareholders over major decisions, including the potential consolidation and rebranding the board may now pursue at its discretion.
Quantum describes itself as a biopharmaceutical company building a portfolio of innovative assets and biotech solutions for neurodegenerative and metabolic disorders and alcohol misuse disorders. Through wholly owned subsidiary Lucid Psycheceuticals Inc., it is focused on lead compound Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Quantum also invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, plus royalties of 7% of sales until payments reach $250 million, after which the rate drops to 3% in perpetuity.
Latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. The announcement was distributed through BioMedWire, a communications platform focused on the biotechnology, biomedical sciences and life sciences sectors and one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and offers editorial syndication to 5,000+ outlets.
